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Mature oligodendrocytes actively increase in vivo
cytoskeletal plasticity following CNS damage
Giuseppe Locatelli1,2, Arianna Baggiolini1†, Bettina Schreiner1†, Pushpalatha Palle4,5, Ari Waisman3,
Burkhard Becher1 and Thorsten Buch1,4,5*
Abstract
Background: Oligodendrocytes are myelinating cells of the central nervous system which support functionally,
structurally, and metabolically neurons. Mature oligodendrocytes are generally believed to be mere targets of
destruction in the context of neuroinflammation and tissue damage, but their real degree of in vivo plasticity has
become a matter of debate. We thus investigated the in vivo dynamic, actin-related response of these cells under
different kinds of demyelinating stress.
Methods: We used a novel mouse model (oLucR) expressing luciferase in myelin oligodendrocyte glycoprotein-
positive oligodendrocytes under the control of a β-actin promoter. Activity of this promoter served as surrogate for
dynamics of the cytoskeleton gene transcription through recording of in vivo bioluminescence following diphtheria
toxin-induced oligodendrocyte death and autoimmune demyelination. Cytoskeletal gene expression was quantified
from mature oligodendrocytes directly isolated from transgenic animals through cell sorting.
Results: Experimental demyelinating setups augmented oligodendrocyte-specific in vivo bioluminescence. These
changes in luciferase signal were confirmed by further ex vivo analysis of the central nervous system tissue from
oLucR mice. Increase in bioluminescence upon autoimmune inflammation was parallel to an oligodendrocyte-
specific increased transcription of β-tubulin.
Conclusions: Mature oligodendrocytes acutely increase their cytoskeletal plasticity in vivo during demyelination.
They are therefore not passive players under demyelinating conditions but can rather react dynamically to external
insults.
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Background
Oligodendrocytes (ODCs) are cells of the central nervous
system (CNS) whose processes form myelin, a multi-layered
membrane structure participating in saltatory signal conduc-
tion [1] and metabolic support of neuronal axons [2,3].
Myelin is produced in the last developmental stage of ODCs
through a rapid, tightly regulated process [4] in which
overlaying contiguous membranes become strongly inter-
connected by extruding cytoplasm to form compact myelin
[5]. These membrane domains remain directly connected to
the cell body with a complex underlying cytoarchitecture
comprising microtubules distributed in larger processes and
actin filaments enriched in thinner myelin domains and in
paranodes [6,7]. β-actin and β-tubulin are thus main players
in dynamics of axon targeting and myelin stability [7,8].
Acute or chronic damage to ODCs inevitably leads to
neuronal loss as observed in several animal models [9-11]
and human diseases such as multiple sclerosis (MS) and
inherited leukodystrophies of the CNS [10]. However, de-
myelination and ODC death also lead to the activation of
oligodendrocyte progenitor cells (OPCs) [11-15]. These
cells can develop into mature ODCs and remyelinate naked
* Correspondence: thorsten.buch@uzh.ch
†Equal contributors
1Institute of Experimental Immunology, University of Zurich,
Winterthurerstrasse 190, Zürich 8057, Switzerland
4Institute for Medical Microbiology, Immunology and Hygiene, Technische
Universität München, Trogerstrasse 30, 80675 Munich, Germany
5Institute of Laboratory Animal Science, VetSuisse, University of Zurich,
Winterthurerstrasse 190, Zurich 8057, Switzerland
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2015 Locatelli et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Locatelli et al. Journal of Neuroinflammation  (2015) 12:62 
DOI 10.1186/s12974-015-0271-2
axons, thus restoring saltatory conduction [16]. In this con-
text, the role of surviving mature ODCs within and sur-
rounding damaged CNS areas is still unclear. While it is
current dogma that mature ODCs lack the ability to remye-
linate axons [13,17], some studies indicate that these cells
can at least maintain different degrees of structural plasti-
city. Earlier observations in different experimental para-
digms and within MS lesions indicate sparse mature ODC
proliferation within remyelinating areas [18-20], and
in vitro ODCs can survive complement attack by actively
shedding myelin vesicles [21], regenerate myelin processes
after damage [22,23], and display migratory capability after
maturation [24]. Also, the fact that ODCs close to or within
neuroinflammatory lesions that have been deprived of their
myelin processes can survive this insult [25,26] suggests the
existence of active mechanisms of cellular plasticity.
Insights into dynamic properties of ODCs could come
from the study of the cell cytoarchitecture which regu-
lates and drives membrane movements [27]. In order to
investigate the plasticity of mature ODCs under demye-
linating conditions in vivo, we have thus generated a
mouse model (oLucR) in which luciferase expression is
controlled by a β-actin promoter and restricted specific-
ally to mature ODCs [28]. CNS-specific bioluminescence
in oLucR mice was quantitatively measured in vivo after
injection of luciferin. We followed bioluminescence
changes in two experimental models of ODC damage,
namely diphtheria toxin (DTx)-mediated ODC killing
(oDTR model [11,29,30]), and in the neuroinflammatory
paradigm experimental autoimmune encephalomyelitis
(EAE) [1]. oLucR mice revealed defined and reprodu-
cible increases in the in vivo bioluminescence during in-
duced demyelination in both experimental paradigms,
independently from de novo ODC generation from pro-
genitors. The measured in vitro and ex vivo biolumines-
cence correlated with the in vivo longitudinal data,
indicating that our observations revealed an intrinsic
feature of the damaged ODC population. Transcriptional
analysis of structural genes in the damaged CNS and
specifically within ODCs showed increased expression of
cytoskeleton genes after demyelinating insult. Our re-
sults thus elaborate in a novel in vivo model previous
suggestions that ODCs undergoing/sensing cellular
stress can transiently enhance their own plasticity
[21-24]; furthermore, we provide important insights on
the timing and extent of such activation in in vivo ex-
perimental demyelination models.
Methods
Animals
Mice were kept under SPF conditions according to Swiss
and German animal laws and institutional guidelines. Ani-
mal experiments were conducted under the license num-
bers 13/2006 and 55.2-1-54-2532-1-12 after approval by
the respective Swiss and German government agencies, the
Veterinäramt of the Canton of Zurich and the Regierung
von Oberbayern. The presence of respective transgenes was
confirmed by PCR analysis on DNA from tail biopsies by
the use of the following primer pairs: MOGi-cre [29] (WT
350 bp) GAC AAT TCA GAG TGA TAG GAC CAG
GGT ATC CC and GCT GCC TAT TAT TGG TAA GAG
TGG; MOGi-cre (knock-in, 700 bp) TCC AAT TTA CTG
ACC GTA CAC and CAT CAG CTA CAC CAG AGA
CGG AAA TC; iDTR [30] (WT 600 bp, KI 845 bp) AAA
GTC GCT CTG AGT TGT TAT, GGA GCG GGA GAA
ATG GAT AAA GTC GCT CTG AGT TGT TAT, GGA
GCG GGA GAA ATG GAT ATG, and AAT AGG AAC
TTC GTC GAG AAT AGG AAC TTC GTC GAG C; Lu-
ciferase (415 bp) TGT TGT TCC ATT CCA TCA CGG
and ATC CAG ATC CAC AAC CTT CGC; and EYFP
(200 bp) CTA TAT CAT GGC CGA CAA GC and ACT
GGG TGC TCA GGTAGT GG.
In vivo bioluminescence recordings and disease models
oLucR mice were shaved and anesthetized, and light emis-
sion was recorded in vivo in an ultrasensitive IVIS 100 sys-
tem (Caliper Life Science, Hopkinton, MA, USA) after
intraperitoneal (i.p.) injection of 150 ng/kg of D-luciferin.
The average photon-per-second recording over the full kin-
etics of the luciferase reaction was used as readout per
mouse, permeasurement.
For EAE experiments, 6- to 10-week-old mice were
immunized subcutaneously with 200 μg (each flank
100 μg) of myelin oligodendrocyte glycoprotein MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK) emulsified in
Complete Freund’s Adjuvant (CFA; H37 Ra, Difco Labora-
tories, Franklin Lakes, NJ, USA), and injected i.p. the
same day and at day 2 with 200 ng pertussis toxin
(Sigma-Aldrich, St. Louis, MO, USA). To deplete ODCs
through DTx administration, 6- to 10-week-old oLucR/
diphtheria toxin receptor (DTR) animals were injected i.p.
with 200 ng DTx (Merck, Darmstadt, Germany) daily over
7 days. EAE scoring and composite score of DTx-induced
clinical disease was performed as in [11].
Ex vivo CNS slices
Animals were killed and perfused with phosphate-buffered
saline (PBS), and CNS were collected and cut in half. From
one half of the brain and spinal cord, approximately 1-
mm-thick slices were cut, bathed in 150 μg/ml luciferin,
and immediately recorded for 2 min within an IVIS 100
system (Caliper Life Science).
Luminometer assay
Mouse tissue was dissolved in lysis buffer (Promega Cor-
poration, Fitchburg, WI, USA). Protein content was
quantified by the Bradford method (Bio-Rad, Munich,
Germany) using BSA as protein standard. Lysates were
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adjusted to same protein content and analyzed according
to manufacturer’s guidelines in a black 96-well plate on
a microplate luminometer (Victor2, Wallac, Freiburg,
Germany).
Immunostaining of cells after cytospin
Cell sorting was carried out using a FACSAria III (BD
Biosciences, San Jose, CA, USA). Dead cells were ex-
cluded using an Aqua Live/Dead staining reagent (Invi-
trogen, Carlsbad, CA, USA) and microglial/myeloid cells
by positive staining for CD45 and CD11b. Sorted EYFP+
ODCs were spun onto glass slides (600 rpm) (Shandon
Southern Instruments, Sewickley, PA, USA). Cells were
fixed in 4% paraformaldehyde (10 min), incubated with 4%
normal goat serum in 0.2% Triton-PBS, and then immuno-
stained. For primary antibodies, goat anti-GFP antibody
(Rockland, Gilbertsville, PA, USA), mouse anti-CC1 (Cal-
biochem, Darmstadt, Germany), rabbit anti-PLP (Abcam,
Cambridge, UK), and Isolectin b4-Alexa Fluor 568 (Sigma-
Aldrich, St. Louis, MO, USA) were used as indicated and
were detected with secondary anti-goat Alexa Fluor 488-,
anti-mouse Alexa Fluor 405-, anti-rabbit Alexa Fluor 647-
conjugated antibody (all by Invitrogen, Carlsbad, CA,
USA). Confocal microscopy was performed using a SP5
confocal laser microscopy (Leica, Wetzlar, Germany)
and images analyzed using Imaris software (version
7.5.1; Bitplane, Zurich, Switzerland).
Expression analysis
Samples were homogenized in 1 ml TRIZOL and incu-
bated for 5 min at room temperature (RT). Two hun-
dred microliters chloroform were added, incubated for
3 min at RT, and centrifuged at 8,000 rpm for 15 min at
4°C. The RNA in the aqueous phase was precipitated by
500 μl isopropyl alcohol (10-min incubation at RT and
centrifugation at 800 rpm for 10 min at 4°C). The RNA
pellet was washed with 1 ml 75% ethanol. Samples were
centrifuged at 5,000 rpm for 5 min at 4°C, and the RNA
pellet was dried for 15 min at RT and dissolved in 45 μl
RNase free water with 5 μl of 10× incubation buffer and
1 μl DNaseI. The samples were incubated at 37°C for
20 min, and then, 1 μl 0.5 M EDTA was added, incu-
bated at 75°C for 10 min, and placed on ice. For FACS-
sorted cell samples, RNA was prepared using an RNeasy
Plus Micro Kit (Qiagen, Valencia, CA, USA). One micro-
liter random primers (100 ng/μl), 1 μl dNTP (10 mM),
4 μl first-strand buffer (5×), 2 μl DTT (0.1 M), and 1 μl
RNase OUT were incubated for 2 min at 37°C, and then,
1 μl M-MLV RT (200 U/μl) was added.
Five micrograms RNA were diluted in 10 μl RNase
free H2O, heated to 65°C for 5 min, and quenched on
ice. Afterwards, 10 μl Master Mix were added to the
RNA, incubated 10 min at 21°C, 50 min at 37°C, and fi-
nally 15 min at 70°C. The cDNA was finally diluted 1:10.
Five microliters of cDNA per real-time reaction were
mixed with 12.5 μl SYBR Green, 6.5 μl H2O, 0.5 μl F-
Primer, and 0.5 μl R-Primer for a total volume of 25 μl.
The real-time (RT-PCR) was performed using a C1000
Touch Thermal Cycler (Bio-Rad CFX384 Real-Time Sys-
tem, Bio-Rad, Munich, Germany) with the following
primers: β-actin, F: AGA GGG AAA TCG TGC GTG
AC; R: CAA TAG TGA TGA CCT GGC CGT; Nestin,
F: CAA GAA CCA CTG GGG TC, R: CCC TCC TGG
TGA TTC CAC A; NG2, F: GTT GGG ATG CTT GCT
GG, R: TGA AAG CTG CAG AAG CA; MOG, F: AAA
TGG CAA GGA CCA AG, R: AGC AGG TGT AGC
CTC CTT; OLIG1, F: ACC AAC GTT TGA GCT TGC
TT, R: GGT TAA GGA CCA GCC TGT GA; β-Tubulin,
F: TCG TGG AAT GGA TCC CCA AC; R: CTC CAT
CTC GTC CAT GCC CT; and RNA polymerase II: CTG
GTC CTT CGA ATC CGC ATC and GCT CGA TAC
CCT GCA GGG TCA.
Immunohistochemistry
Mice were euthanized with CO2 and perfused with
PBS. For cryostat sections, the tissue was fixed over-
night with 4% PFA, cryoprotected in 30% sucrose and
frozen at −80°C. Frozen tissue was cut sagittally in 40-
μm-thick sections and stained with myelin basic protein
(MBP)-specific (Dako, Glostrup, Denmark) and β-actin-
specific (Biolegend, San Diego, CA) antibodies. Detection
was accomplished using Alexa fluor-coupled secondary
antibodies (Life Technologies, Karlsruhe, Germany). Sec-
tions were covered with Vectashield (Vector Laboratories,
Burlingame, CA) and analyzed by confocal (Leica SP7,
Leica, Wetzlar, Germany) microscope.
Statistical analysis
Unless otherwise indicated, data were displayed as mean ±
SEM, and statistical analysis performed by two-tailed
Student’s t test using Excel software (Microsoft). Disease
onset/bioluminescence increase correlation analysis was
performed by Pearson’s correlation coefficient analysis.
Results
In vivo bioluminescence in the oLucR mouse model is
specific for mature ODC
The aim of our study was to investigate cellular dynam-
ics of ODCs in an in vivo mouse model. As microfila-
ment dynamics control the fine morphological changes
during OPC migration, differentiation, and ODC myelin-
ation, the activation of the β-actin promoter was used as
indirect readout of ODC plasticity. We generated a
mouse model (oLucR) in which activity of the β-actin
promoter can be monitored specifically within ODCs
through luciferase expression. We achieved this by using
a strain in which luciferase was driven by the β-actin
promoter but its expression restricted to ODCs through
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excision of a loxP-flanked STOP cassette by the MOGi-
cre strain specific for mature ODCs [28,29] (Figure 1a).
Specificity and efficacy of the Cre-mediated recombin-
ation for terminally differentiated ODCs were tested by
breeding the MOGi-cre mouse line with the EYFP re-
porter line, in which expression of the fluorescent pro-
tein EYFP was dependent on excision of a STOP
cassette. Between 65% and 95% of CC1+, ODCs showed
efficient locus recombination, depending on the CNS re-
gion (data not shown). To further characterize these
cells, we FACS-sorted EYFP+ cells from dissociated CNS
tissue of MOGi-cre x EYFP reporter mice. FACS-sorted
ODCs appeared devoid of myelinated processes but
remained alive (see ‘Methods’ section) and stained posi-
tive for PLP (myelin proteolipid protein) and CC1, both
markers of mature ODCs (Figure 1b). Also, RT-PCR of
sorted EYFP+ cells revealed strong expression of the ma-
ture ODC marker gene MOG and no expression of the
precursor markers NG2 or nestin (data not shown). We
could thus confirm ex vivo that mature ODCs physically
deprived of their myelin sheaths can indeed survive the
insult [23,25,26]. Taken together, Cre activity in MOGi-
cre mice was confirmed to be restricted to mature ODC.
In vivo bioluminescence in oLucR mice was visualized
and quantified in an IVIS 100 system (Caliper Life Sci-
ence) after i.p. injection of 150 ng/kg of luciferin. The
luciferase signal was characterized by reproducible kinet-
ics of photon emission showing an emission peak
10 min after luciferin injection (Figure 1c). Since minor
photon emission was also detected from non-CNS areas
(such as liver, tail, and paws), we recorded the luciferase
signal from specific regions of interest (ROIs) covering
the brain and spinal cord (Figure 1d). While faint bio-
luminescence signals from the liver and spleen were ex-
pected [28], photon emission from the tail and paws
proved to be an in vivo artifact, as freshly dissected tails
and limbs did not show any luciferase expression ex vivo
(data not shown). As expected, absolute luciferase content
in the CNS of oLucR mice increased during postnatal de-
velopment reflecting ODC maturation and thereby MOG
expression [31] (Figure 1e). Longitudinal analysis of the
luciferase signal in adult oLucR mice showed stable
luciferase-driven bioluminescence over extended time pe-
riods (up to 5 weeks), as a consequence of steady-state ex-
pression of β-actin gene in undisturbed myelin (Figure 1f).
Taken together, we showed that the oLucR system was
suitable to indirectly visualize the in vivo activity of the β-
actin promoter within mature ODCs.
DTx-mediated ODC death increases overall ODC β-actin
promoter activity
ODC death and demyelination are pathological hallmarks
of several human CNS diseases such as certain hereditary
and metabolic leukodystrophies and MS [1,32]. While it
has been shown in several animal models that remyelina-
tion by differentiating OPCs follows myelin destruction
[16], the behavior of the surviving mature ODC population
in response to demyelinating stress or even death of nearby
ODCs is still unclear. To investigate dynamics of the cyto-
skeleton in mature ODCs after demyelinating insults, we
used the oDTR system [11] for experimental ODC death.
We crossed oLucR mice to the iDTR strain [30] to obtain
DTR expression specifically on MOG+ ODC. We recently
showed that in the resulting oDTR system, DTx adminis-
tration leads to a highly specific ablation of up to 60% of
ODCs in disseminated white matter areas, followed by
diffuse demyelination starting 1 week post administration
(p.a.) [11]. In this model, surviving unaffected mature
ODCs are often located scattered within demyelinated areas
or in close proximity to damaged ODC neighbors [11].
We injected into these oLucR/oDTR and into control
oLucR mice 200 ng of DTx daily for a week. As a conse-
quence of damage to the ODC population, DTx-treated
oLucR/oDTR mice, but not oLucR control mice, presented
with progressive and severe motor impairment starting
5 weeks p.a. (Figure 2a). In oLucR/oDTR mice, biolumines-
cence increased approximately threefold compared to the
basal level during the first week of DTx administration
(Figure 2b), parallel to the initial demyelination classically
observed in the oDTR model [11]. To confirm that this sig-
nal peak was not the result of a damaged blood brain bar-
rier (BBB) and thus easier access of luciferin to the brain
parenchyma, we performed additional analyses. First,
freshly prepared brain slices were placed in luciferin
followed by ex vivo analysis of light emission (Figure 2c);
second, total brain lysates were assessed by luminometer
measurements at the end of the demyelination period
(Figure 2d). Both assays confirmed increased luciferase ex-
pression in the CNS of DTx-treated oLucR/oDTR mice
compared to controls. Furthermore, to support our obser-
vation obtained with the transgenic luciferase reporter sys-
tem, we analyzed β-actin RNA levels in samples from
different CNS areas. Since β-actin was the gene of interest
in our analysis, we utilized transcript level of RNA poly-
merase II as housekeeping gene and internal control in this
and following assays [33]. We found that, in contrast to the
decrease in MOG expression (Figure 2e), β-actin was up-
regulated in all CNS regions during the initial period of in-
creased in vivo luciferase activity (Figure 2f). Taken
together, sterile ODC ablation led to increased ODC-
specific, β-actin-driven bioluminescence, thus suggesting
activation of cytoskeletal plasticity in ODCs upon demye-
linating stressors.
Increased activity of β-actin-driven luciferase at onset of
autoimmune CNS inflammation
DTx-mediated pathology derives from direct, sterile in-
sults to ODCs [11]. Yet, the most common demyelinating
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disease in humans is MS, in which an inflammatory
process results in demyelination and axonal degeneration
[34]. To assess whether immune-mediated damage to the
CNS would induce an active plastic reaction of the mature
ODC compartment, we measured the β-actin-driven bio-
luminescence response in oLucR mice in the EAE model.
Mice were immunized against a myelin-derived peptide
(MOG35–55), leading to a T cell-mediated attack against
CNS myelin and to direct and indirect insults to ODCs
[9]. In this system, a variable degree of demyelination and
cell death is observed, predominantly in the spinal cord
and brain stem [1]. We thus recorded bioluminescence
every 2 to 3 days in immunized and in naïve control
(oLucR) animals. After a transient increase in biolumines-
cence at day 2 post immunization (p.i.), we detected a
sharp, approximately 12-fold increase in luciferase signal
compared to baseline (Figure 3a,b). Such bioluminescence
increase was observed consistently at the disease onset in
MOG35–55-immunized oLucR mice (Figure 3a,b) and was
followed by a sharp decrease in bioluminescence almost
reaching levels found before immunization and in naïve
animals (Figure 3b). Notably, the acute peak in biolumin-
escence consistently correlated with the beginning of clin-
ical EAE signs independent of the exact time point of
disease onset (Figure 3c). At the same time, biolumines-
cence in MOG-immunized oLucR mice that did not
Figure 2 Toxin-induced ODC death and demyelination leads to increased bioluminescence in oLucR mice. (a) Composite score of clinical
disability in DTx-treated oLucR/DTR and control oLucR mice (n= 5). Details of score in [11]. (b) Ratio of mean CNS-specific bioluminescence between
DTx-injected oLucR/DTR and oLucR control mice imaged in an IVIS three times a week. Data are representative of two independent experiments (n= 10).
The red line indicates the mean baseline photon emission before DTx treatment. The blue bar indicates the period of DTx treatment. (c) Representative
pictures of freshly prepared luciferin-bathed brain slices from DTx-treated oLucR/DTR and oLucR control mice 7 weeks p.a. An overlay of photographic
picture and photon emission is shown. (d) CNS from DTx-treated oLucR/DTR and control oLucR mice 7 weeks p.a. were dissected, and lysates were
analyzed by luminometer (mean ± SEM, n= 4). Gene expression changes in the CNS of oDTR and control mice following DTx treatment. mRNA levels of
MOG (e), and β-actin (f) were measured in oLucR/DTR and control mice 9 days after DTx injections (n= 4, mean ± SEM). OB = olfactory bulb;
CC = corpus callosum.
(See figure on previous page.)
Figure 1 The oLucR mouse model shows CNS-specific in vivo bioluminescence. (a) ODC-specific expression of luciferase is achieved by
crossing a Cre-inducible luciferase reporter mouse (left) to the MOGi-cre strain. (b) EYFP+ cells were sorted and stained with CC1-, GFP-, Iba1-, and
PLP-specific antibodies following cytospin. Microglia/macrophage cells were excluded by positive CD45 and CD11b staining. Dead cells were
excluded by Aqua Live/Dead staining reagent (Life Technologies). (c) Kinetics of photon emission acquired with an IVIS camera in anesthetized
oLucR animals following intraperitoneal injection of 150 ng/kg of D-luciferin (mean ± SEM, n= 8). (d) In vivo bioluminescence recorded in a representative
oLucR mouse (left) and a control LucR animal where the STOP codon impedes luciferase expression (right). Shown in red are the specific regions of interest
(ROIs) for signal acquisition. (e) The CNS from oLucR mice of the indicated ages were homogenized and analyzed in a luminometer assay. Photon emission
of the lysates is shown (mean ± SEM, n= 3). (f) oLucR mice were injected with luciferin every 3 days and bioluminescence recorded from specific brain
and spinal cord ROIs over the course of 36 days (mean ± SEM, n= 4).
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develop overt clinical paralysis remained unchanged over
time (data not shown). This also indicated that not MOG
immunization per se, but injury to ODCs and subsequent
neurological deficits were closely related to actin/cytoskel-
eton ODC dynamics. We then tested whether increase in
bioluminescence could have been the result of higher
access of luciferin to the CNS. First, we investigated
whether the adjuvant pertussis toxin (PT) alone, known to
transiently increase BBB permeability [35,36], could affect
in vivo bioluminescence in our model. PT administration
in oLucR animals resulted in a low and transient increase
in luciferase signal (Figure 3d), similar to the minor bio-
luminescence increase observed in the EAE experiment 1
to 5 days post immunization (Figure 3b). Second, we im-
munized oLucR animals with MOG35–55 in CFA and ana-
lyzed luciferin-bathed brain slices every other day from
Figure 3 CNS autoimmune inflammation leads to increased bioluminescence in oLucR mice at clinical onset of disease. (a) EAE disease
scores in MOG-immunized oLucR animals (mean ± SEM, n = 5). (b) Ratio of mean CNS-specific bioluminescence between MOG-immunized and
control mice imaged in an IVIS every 2 to 3 days after immunization. Data are representative of three independent experiments (n= 15). The red line
indicates the baseline photon emission before MOG immunization. (c) Linear correlation between day of clinical onset and increase of bioluminescence in
MOG-immunized oLucR mice (n = 15, Pearson’s correlation coefficient = 0.9989). The three mice with disease onset around day 40 did not develop
clinically overt EAE after the initial EAE induction and therefore were re-immunized with MOG peptide after 1 month. (d) Ratio of mean CNS-specific
bioluminescence between PT-treated and control mice. oLucR mice were injected with 300 ng PT at day 0 and 2 and bioluminescence acquired over
time (n = 5). The red line indicates baseline photon emission before PT administration.
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day 5 to day 15 p.i. Ex vivo bioluminescence followed
similar dynamics as the one observed in vivo, with in-
creased luciferase signals detected in all CNS regions of
mice developing clinical EAE, albeit predominantly in the
severely affected spinal cord (Figure 4a,b). In contrast,
CNS slices from immunized mice that were found not to
develop the disease did not show any increase in ex vivo
bioluminescence (data not shown). Third, in vitro analysis
of luciferase activity of CNS lysates revealed increased re-
porter levels especially in the spinal cord and brain stem
of EAE-induced animals compared to controls (Figure 4c).
Thus, intrinsic damage-related dynamical responses of the
cytoskeleton within the ODC population account for the
major bioluminescence changes observed in oLucR mice.
To further investigate the nature of the bioluminescence
increase at EAE onset, we immunized oLucR animals and
analyzed gene expression in the spinal cord at day 11 p.i.
We observed a decrease in ODC markers such as
MOG and Olig1 (Figure 5a,b), while β-actin levels were
strongly increased specifically in oLucR animals in-
duced with EAE (Figure 5c). Notably, 5 days after clin-
ical EAE onset, at the beginning of the ameliorating
remitting phase, β-actin expression decreased almost
reaching control levels (Figure 5d). As several invading
immune cells and resident activated glial cells might
contribute to the observed dynamics in whole-tissue β-
actin transcription, we FACS-isolated mature EYFP+
ODCs from naïve and MOG-immunized EYFP reporter
mice and analyzed expression level of cytoskeletal genes
within these cells. In this assay, β-actin levels appeared un-
changed in ODCs during the course of EAE (Figure 5e).
However, β-actin mRNA is known to be transported to
distal sites and leading edges within cells [37,38]. Our flow
cytometry purification approach necessarily shed distal
myelin processes from isolated ODCs (Figure 1b). Ac-
cordingly, immunostaining of spinal cord sections
showed increased presence of β-actin in myelin struc-
tures and ODC processes at disease onset compared to
controls (Figure 5e). To investigate other changes in
cytoskeleton gene expression, we then analyzed the
major component of ODC cytoskeleton, β-tubulin, for
which distal mRNA transport has not been described.
Our analysis indeed revealed significant upregulation of
β-tubulin expression in mature ODCs at clinical onset
of EAE compared to control naïve mice (Figure 5f ).
Altogether, in vivo and ex vivo analysis of oLucR mice in-
dicates that CNS inflammation induces drastic changes in
cytoskeletal genes within the ODC population.
Discussion
ODCs were originally thought to provide mere structural
requirements for saltatory signal transduction of neurons.
Only in recent years, they found increasing recognition as
fundamental supporters of neuronal metabolism and sur-
vival and have thus obtained attention for their active role
in many neurodegenerative pathologies [2,3,10]. Mature
ODC death and demyelination directly promote the devel-
opment and accumulation of clinical disabilities within de-
myelinating diseases such as MS, leukodystrophies, and
respective animal models [11,32]. Following such patho-
logical processes, stem cells and OPCs enable a functional
healing process through remyelination of insulted CNS
areas. The current paradigm holds that during such in-
sults and subsequent remyelination, postmitotic ODCs re-
main passive victims of damage [16]. In contrast to this
traditional viewpoint, different studies support the hy-
pothesis that mature ODCs actively respond to parenchy-
mal stress [39] and maintain some degree of structural
Figure 4 Ex vivo and in vitro increase in CNS-specific bioluminescence during neuroinflammation. (a) Representative freshly dissected
luciferin-bathed brain slices from oLucR animals at different time points following MOG immunization. An overlay of photographic picture and
photon emission is shown. The EAE score at the time of analysis is shown below the individual pictures. (b) Representative freshly dissociated
luciferin-bathed brain slices and whole spinal cords from MOG-immunized animals and not immunized control mice. Overlay of photographic
picture and photon emission is shown. (c) CNS from MOG-immunized and control oLucR mice 25 days p.i. were dissected, and luciferase activity
within lysates was analyzed by luminometer (mean ± SEM, n = 4).
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plasticity potentially enabling not only ODC survival dur-
ing neuroinflammation but also complex dynamic adapta-
tion upon environmental cues [21-25]. Unfortunately,
little is known about the in vivo response and potential
functional plasticity of mature ODCs upon demyelinating
insults. Underlying the complex cytoarchitecture of
ODCs, β-actin and β-tubulin are necessary candidates as
main players in ODC and myelin dynamics. Even though
both have been traditionally considered housekeeping
genes, their transcriptional control can be substantially af-
fected during cell proliferation, activation, differentiation,
membrane fragmentation, and in the context of different
pathological conditions [33,40-42]. We therefore chose
the β-actin promoter in combination with luciferase as a
readout to investigate the fine in vivo dynamics of mature
ODCs. Given its low background, high quantum yield,
and good tissue penetration, the luciferase reporter is
widely used in macroscopic in vivo measurements [43]. In
our oLucR mouse model, luciferase expression is con-
trolled by the β-actin promoter and restricted to MOG-
expressing ODCs by a Cre/loxP system. Luciferase activity
in these mice increased during CNS development
followed by a stable, reproducible signal intensity in adult
animals, as expected from the known sequence of myelin-
ation events [31]. Cre/loxP recombination was highly ef-
fective and specific for mature, PLP+MOG+NG2negative
ODCs. Thus, oLucR mice allowed us to follow in vivo bio-
luminescence changes specifically from the terminally dif-
ferentiated ODC population.
In this study, different experimental insults to myelin
and ODCs led to a consistent augmentation of ODC-
specific bioluminescence in oLucR mice. First, in the
oDTR model [11], widespread ODC death through DTx
administration in oLucR/oDTR mice transiently albeit
consistently increased in vivo bioluminescence. Second,
a strong rise in luciferase signal was observed after auto-
immune inflammatory myelin and ODC damage, correl-
ating with the clinical disease onset of EAE in oLucR
mice. Such variations in luciferase levels appeared intrin-
sic to the demyelinating CNS as ex vivo and in vitro
Figure 5 RT-PCR analysis in the CNS of MOG-immunized versus control mice reveal upregulated expression of cytoskeleton genes.
mRNA levels of MOG (a), NG2 (b), and β-actin (c) were measured in MOG-immunized and not immunized (control) oLucR mice at clinical onset
of EAE (d) or at onset +5 (mean of EAE/control ratio ± SEM, n = 5). (e) Sagittal sections of spinal cord from mice at disease onset and controls
were immunostained with MBP- and actin-specific antibodies. Shown are representative pictures of ODCs in white matter areas (n = 3). Scale
bar, 6 μm. (f) Relative mRNA expression in FACS-sorted EYFP+ ODCs from the CNS of MOG peptide immunized mice and naïve controls at day of
clinical onset of EAE (mean ± SEM, n = 5). Two-tailed Student’s t test, *P < 0.05.
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analysis of freshly cut CNS slices and CNS protein ex-
tracts confirmed these in vivo results. Altogether, despite
the possibility of signal loss due to ODC death and re-
duction in ODC numbers, demyelinating conditions led
to a consistent increase in the ODC-specific luciferase
reporter signal. The post-lesion timing of such biolumin-
escence changes clearly rules out any possible signal
contribution from recruited/differentiated OPCs. PT
adjuvant treatment alone, known to increase BBB per-
meability, resulted in a transient and low signal augmen-
tation, suggesting that enhanced luciferin access to the
CNS can account only for a small proportion of the ob-
served fluctuations. We did not formally exclude a direct
‘activatory’ effect of PT on ODCs [44], but this seems
unlikely due to the delayed occurrence of enhanced
in vivo bioluminescence in the EAE model. Nonetheless,
the relatively fast decline of in vivo bioluminescence fol-
lowing the rapid increases in luciferase emission at clin-
ical onset of EAE or during DTx administration in
oLucR/DTR mice remains somewhat puzzling. In DTx-
injected oLucR/oDTR mice, the drastic drop in bio-
luminescence can be easily ascribed to the massive ODC
degeneration observed 1 week post DTx administration
[11]. However, death of luciferase+ ODCs alone cannot
explain the bioluminescence decrease following the
emission peak observed during EAE, as ODC death in
such paradigm is neither massive nor sharply-timed. Ra-
ther, such emission kinetics might indicate that mature
ODC ‘activation’ represents a transient process which
closely mirrors the strong, destructive inflammation ob-
served in the early phases of EAE. Also, increased tissue
hypoxia in the inflamed spinal cord [45,46] could dir-
ectly contribute to the decrease in bioluminescence fol-
lowing disease onset, as luciferase activity is highly
dependent on the amount of oxygen available [47].
Overall, the consistent increase of in vivo and in vitro
bioluminescence upon immune- or toxin-mediated de-
myelination/ODC damage suggests that luciferase+ ma-
ture ODCs exhibit some kind of stress-induced acute
activation of the cytoskeleton encoding genes within and
surrounding experimental demyelinating lesions.
Accordingly, total β-actin expression was higher in the
CNS of EAE-induced oLucR and DTx-treated oLucR/
oDTR mice than in control mice. We have previously
shown that in the oDTR model, no lymphocyte infiltra-
tion, OPC recruitment, microglia or astroglia activation
can be observed 1 week after induction of demyelination
[11]. Therefore, in the DTx-treated oLucR/oDTR mouse
model, the early increase in actin transcription can be as-
cribed to a transient mobilization of mature luciferase+
ODCs, which were not killed by DTx. Surviving mature
ODCs in the oDTR model are generally located in close
proximity to damaged cells and within demyelinating
CNS areas [11]. ODCs could thus sense pathological
changes of dying neighboring ODCs through soluble me-
diators or via gap junctions within the glial syncytium
[48]. However, in oLucR mice at clinical onset of EAE, the
observed increase in CNS β-actin expression is likely af-
fected by inflammatory processes such as leukocyte infil-
tration and glial activation. We thus performed
immunostaining of myelin and β-actin in white matter
areas at onset of EAE and observed stronger expression of
β-actin in ODC processes and attached myelin sheaths.
Additionally, we repeated RNA expression analysis on
purified mature ODCs through FACS-sorting of EYFP+
ODCs but found no difference in β-actin expression upon
onset of clinical EAE in sorted ODCs. This apparent con-
undrum could result from our technical approach of cell
purification, as our RT-PCR data can only provide infor-
mation on mRNA content of the ODC cell body, but not
on distally transported mRNAs, which are highly enriched
in myelin (that is, MBP mRNA [49,50]). Such mechanism
of distal transport and translation has been indeed exten-
sively described for β-actin mRNA [37,38] and allows
higher polymerization rate of microfilaments and in-
creased cell motility in the leading edge of dynamic cellu-
lar structures. It is thus likely that mature ODCs enhance
β-actin expression and mRNA distal transport in vivo
upon demyelinating stress. Different from β-actin mRNA
particles, β-tubulin mRNA is not transported to distal cel-
lular compartments, as microtubules are very rare in thin
villi of mature cells and leading edges of myelinating pro-
genitors compared to microfilaments [51]. Through our
expression analysis on purified MOG+ cells, we could thus
show for the first time that β-tubulin is significantly in-
creased in mature ODC cell bodies at clinical onset of
CNS inflammation. Altogether, demyelination/ODC dam-
age leads to upregulation of the main component of the
cytoskeleton, β-tubulin, and hints toward an enhanced
distal distribution of upregulated β-actin mRNA in acti-
vated mature ODCs.
Conclusions
Our study addresses a long-standing issue on the biology
of mature ODCs within demyelinating CNS: the current
perception of postmitotic ODCs as simple passive victims
of insults to the myelin. This notion is put under discus-
sion by studies describing different degrees of structural
plasticity of mature ODCs in different in vivo and in vitro
experimental scenarios and the presence of significant
mechanisms of myelin remodeling existing throughout
adulthood [5,18-26,52]. Accordingly, the oLucR model
allowed us to 1) indirectly show through the activity of a
β-actin-driven reporter gene and 2) directly prove through
immunohistochemistry and expression analysis of dam-
aged CNS/sorted cells, that mature ODCs experience a
dynamic in vivo activation of the cytoskeleton possibly
leading to reorganization of myelin sub-structures. Our
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observations thus suggest that mature ODCs can actively
respond to various demyelinating CNS insults, increase
their cytoskeletal plasticity in vivo upon different types of
parenchymal stress, and may thus constitute potential tar-
gets for therapies aimed at supporting neuroprotection/
remyelination.
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